NCT01574612已完成3 期
An Open Label Multi Center Phase III Subject/Caregiver Initiated Safety Study of Xerese(Acyclovir and Hydrocortisone)Cream 5%/1% in the Treatment of Recurrent Herpes Labialis in Children
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 54
- 试验地点
- 10
- 主要终点
- Reporting of Adverse Events
研究概览
简要总结
To test the safety of Xerese (acyclovir and hydrocortisone)Cream 5%/1% for the treatment of recurrent cold sores in children ages 6-11yrs after 5 days of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 11 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, age 6-11 years at time of enrollment
- •General good health, as judged by the Investigator
- •History of recurrent herpes labialis with at least two (2) recurrences during the last twelve (12) months, as based on interview with the subject or subject's caregiver
- •Agreement to refrain from using other topical medical, over-the counter (OTC), or cosmetic products in or around the oral area during the herpes recurrence
- •Agreement to refrain from mechanical disruption of the area affected by herpes labialis during the study recurrence
- •Subjects and their legally acceptable representative(s) must voluntarily sign and date the informed assent (subject) and consent (legally authorized representative).
- •Willingness to comply with all requirements of the study.
排除标准
- •Any evidence of an immunosuppressed state of the subject due to underlying disease (e.g. HIV infection) or concomitant treatment (e.g. cancer chemotherapy)
- •Significant skin conditions that occur in the area typically affected by herpes recurrences, and that would interfere with assessment of lesions such as atopic dermatitis, acne, eczema, psoriasis or chronic vesiculobullous disorders
- •Administration of an investigational drug or within 30 days prior to inclusion, or concurrent participation in another research study
- •Administration of an immunomodulatory agent within the past 30 days
- •History of immediate hypersensitivity or serum sickness reaction to any nucleoside analog antiviral agent, or to any topical steroid, or to the vehicle
- •Clinically relevant abnormal physical findings at screening which, in the opinion of the investigator, would interfere with the objectives of the study or that may preclude compliance with the study procedures Nursing or pregnant (Pubescent females require pregnancy testing)
研究组 & 干预措施
topical cream acyclovir/hydrocortisone
Experimental
topical cream acyclovir/hydrocortisone used
干预措施: acyclovir/hydrocortisone cream (Drug)
结局指标
主要结局
Reporting of Adverse Events
时间窗: day 1 to day 21
treatment period is for 5 days and follow up visits at 7days and 21 days after first dose
次要结局
未报告次要终点
研究者
研究点 (10)
Loading locations...
相似试验
已完成
3 期
Open-label, Extension Study of CDP870 in Patients With Rheumatoid ArthritisRheumatoid ArthritisNCT01197066Korea Otsuka Pharmaceutical Co., Ltd.110
已完成
3 期
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of ObesityBardet-Biedl SyndromePOMC Deficiency ObesityPCSK1 Deficiency ObesityLEPR Deficiency ObesityNCT04966741Rhythm Pharmaceuticals, Inc.12
已完成
3 期
Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia AHemophilia ANCT04323098BioMarin Pharmaceutical22
已完成
3 期
A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor OveractivityNeurogenic Detrusor OveractivityNCT01565694Astellas Pharma Europe B.V.76
已完成
3 期
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed TherapyBreast CancerNCT01419197Hoffmann-La Roche602